SCHEMBL7149747

SCHEMBL7149747

CSc1nc(-c2ccco2)nc(-c2ccco2)c1C#N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.55
KDM4E B2RXH2 9/20 0.55
HPGD P15428 8/20 0.55
MEN1 O00255 7/20 0.55
KMT2A Q03164 7/20 0.55
HSD17B10 Q99714 7/20 0.55
POLB P06746 5/20 0.55
TSHR P16473 3/20 0.55
USP2 O75604 2/20 0.55
NPSR1 Q6W5P4 3/20 0.54
ADORA2A P29274 6/20 0.48
ADORA1 P30542 6/20 0.48
ADORA2B P29275 4/20 0.48
MAPT P10636 4/20 0.44
BLM P54132 3/20 0.44
ALOX15 P16050 2/20 0.44
PTPN7 P35236 2/20 0.44
RECQL P46063 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30229149 0.86 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL6441106 0.85 ADORA2A (0.64) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL7402584 0.80 MEN1 (0.64) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL6440535 0.77 ADORA2A (0.51) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL7406893 0.76 ADORA1 (0.46) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL7400218 0.75 SQOR (0.57) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL6441030 0.74 KDM4E (0.75) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL1176355 0.74 ALDH1A1 (0.54) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL1176202 0.74 KMT2A (0.58) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL6441186 0.73 ALDH1A1 (0.62) ALDH1A1KDM4EHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ALDH1A1 534/4885KDM4E 3250/4885HPGD 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.